MADISON HEIGHTS, Mich.,
Oct. 18, 2017 /PRNewswire/ --
InfuSystem Holdings, Inc. (NYSE American: INFU)
("InfuSystem" or the "Company"), a leading provider of oncology
infusion pumps and related services in North America, announced a feature segment
that recently ran on a leading cable TV channel highlighting how
InfuSystem infusion technology improves the quality of life of a
patient going through the process of receiving chemotherapy.
Entitled "At-Home Infusion Made Easy," the segment ran on "The
Balancing Act" Lifetime TV morning show on October 5th. The segment can be viewed on-demand
at www.infusystem.com/LifetimeTV .
Featured in the segment is one of the over 300,000 new patients
with gastrointestinal cancers that are estimated by the American
Cancer Society to be diagnosed annually in the U.S. InfuSystem
treats a large number of these patients with hardware, medication
and services that serve as the gold standard in the industry.
"I get to get my chemo on the run... and that makes my life a
whole lot easier," said the patient of his InfuSystem experience.
As shown in the Lifetime TV segment, InfuSystem patients are able
to spend more time in the comfort of their own home while receiving
their infusion therapy.
Rich DiIorio, Executive Vice
President at InfuSystem, said, "You'll see a great example of how
InfuSystem patients are able to receive critically-important
treatment in the comfort of their own homes. This allows them to
continue to engage in the activities that are important to them, as
opposed to spending their time in a hospital or infusion
clinic."
"When it comes to immunocompromised chemotherapy patients," Mr.
Dilorio continued, "more time in a hospital is generally not a good
thing given the risk of hospital-borne infection, the anxiety
resulting from being away from home, and the extraordinary costs
associated with hospital stays."
"We hope that the Lifetime segment featuring a patient sharing
his at-home experience with a broadcast audience will help to
empower viewers, some of whom are currently, or at some point in
the future will be, diagnosed with a treatable form of cancer, to
learn more about their infusion therapy options, and thus make
better-informed decisions about their own care and treatment."
The segment aired on Lifetime TV and will continue to air on
affiliate stations. The segment may also be viewed on-demand at
www.infusystem.com/LifetimeTV .
About InfuSystem Holdings, Inc.
InfuSystem Holdings, Inc. is a leading provider of infusion
pumps and related services to hospitals, oncology practices and
other alternate site healthcare providers. With headquarters in
Madison Heights, Michigan, the
Company delivers local, field-based customer support and also
operates Centers of Excellence in Michigan, Kansas, California, Texas, Georgia and Ontario,
Canada. The Company's stock is traded on the NYSE American
under the symbol INFU.
Forward-Looking Statements
Statements made in this press release that are not
historical facts are considered to be forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended (the "Securities Act") and Section 21E of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"). The words
"believe," "may," "will," "estimate," "continue," "anticipate,"
"intend," "should," "plan," "expect," "strategy," "future,"
"likely," variations of such words, and other similar expressions,
as they relate to the Company, are intended to identify
forward-looking statements. However, the absence of these words or
similar expressions does not mean that a statement is not
forward-looking. Forward-looking statements include statements
relating to future actions, business plans, objectives and
prospects, future operating or financial performance. In connection
with the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995, the Company is identifying certain
factors that could cause actual results to differ, perhaps
materially, from those indicated by these forward-looking
statements. Those factors, risks and uncertainties include, but are
not limited to, potential changes in overall healthcare
reimbursement, including CMS competitive bidding, sequestration,
concentration of customers, increased focus on early detection of
cancer, competitive treatments, dependency on Medicare Supplier
Number, availability of chemotherapy drugs, global financial
conditions, changes and enforcement of state and federal laws,
natural forces, competition, dependency on suppliers, risks in
acquisitions & joint ventures, U.S. Healthcare Reform,
relationships with healthcare professionals and organizations,
technological changes related to infusion therapy, dependency on
websites and intellectual property, the ability of the Company to
successfully integrate acquired businesses, dependency on key
personnel, dependency on banking relations and covenants, and other
risks associated with our common stock, as well as any litigation
to which the Company may be involved in from time to time; and
other risk factors as discussed in the Company's annual report on
Form 10-K for the year ended December 31,
2016 and in other filings made by the Company from time to
time with the Securities and Exchange Commission, including our
quarterly reports on Form 10-Q. Our annual report on Form 10-K is
available on the SEC's EDGAR website at
www.sec.gov, and a copy may also be obtained by
contacting the Company. All forward-looking statements made in this
press release speak only as of the date hereof. We do not intend,
and do not undertake any obligation, to update any forward-looking
statements to reflect future events or circumstances after the date
of such statements, except as required by law.
Additional information about InfuSystem Holdings, Inc. is
available at
www.infusystem.com.
CONTACT:
Joe Dorame, Joe
Diaz & Robert Blum
Lytham Partners, LLC
602-889-9700
View original content with
multimedia:http://www.prnewswire.com/news-releases/lifetime-tv-highlights-the-quality-of-life-infusystem-oncology-therapy-can-provide-300538617.html
SOURCE InfuSystem Holdings, Inc.